BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 31731047)

  • 1. Effects of interferon and glatiramer acetate on cytokine patterns in multiple sclerosis patients.
    Ganji A; Monfared ME; Shapoori S; Nourbakhsh P; Ghazavi A; Ghasami K; Mosayebi G
    Cytokine; 2020 Feb; 126():154911. PubMed ID: 31731047
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Elispot assay detection of cytokine secretion in multiple sclerosis patients treated with interferon-beta1a or glatiramer acetate compared with untreated patients.
    Jansson A; Ernerudh J; Kvarnström M; Ekerfelt C; Vrethem M
    Mult Scler; 2003 Oct; 9(5):440-5. PubMed ID: 14582766
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Assessment of CCL27 and IL-11 in Multiple Sclerosis Patients Treated with Interferon-β and Glatiramer Acetate.
    Ebrahimi Monfared M; Shapoori S; Mosayebi G; Khansarinejad B; Ghazavi A; Rezagholizamenjany M; Ganji A
    Neuroimmunomodulation; 2019; 26(6):301-306. PubMed ID: 31935737
    [TBL] [Abstract][Full Text] [Related]  

  • 4. TH1/TH2 Cytokine profile in relapsing-remitting multiple sclerosis patients treated with Glatiramer acetate or Natalizumab.
    Oreja-Guevara C; Ramos-Cejudo J; Aroeira LS; Chamorro B; Diez-Tejedor E
    BMC Neurol; 2012 Sep; 12():95. PubMed ID: 22989378
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Multiple sclerosis: expression of CD1a and production of IL-12p70 and IFN-gamma by blood mononuclear cells in patients on combination therapy with IFN-beta and glatiramer acetate compared to monotherapy with IFN-beta.
    Hussien Y; Sanna A; Söderström M; Link H; Huang YM
    Mult Scler; 2004 Feb; 10(1):16-25. PubMed ID: 14760948
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Short-term treatment of relapsing remitting multiple sclerosis patients with interferon (IFN)-beta1B transiently increases the blood levels of interleukin (IL)-6, IL-10 and IFN-gamma without significantly modifying those of IL-1beta, IL-2, IL-4 and tumour necrosis factor-alpha.
    Nicoletti F; Di Marco R; Patti F; Zaccone P; L'Episcopo MR; Reggio E; Xiang M; Nicoletti A; Reggio A
    Cytokine; 2000 Jun; 12(6):682-7. PubMed ID: 10843745
    [TBL] [Abstract][Full Text] [Related]  

  • 7. IFN-beta1a and IFN-beta1b have different patterns of influence on cytokines.
    Sega S; Wraber B; Mesec A; Horvat A; Ihan A
    Clin Neurol Neurosurg; 2004 Jun; 106(3):255-8. PubMed ID: 15177779
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Th1, Th2 and Th17 Cytokine Profile in Patients with Multiple Sclerosis Following Treatment with Rapamycin.
    Salehi M; Bagherpour B; Shayghannejad V; Mohebi F; Jafari R
    Iran J Immunol; 2016 Jun; 13(2):141-7. PubMed ID: 27350635
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Differential Transcription of SOCS5 and SOCS7 in Multiple Sclerosis Patients Treated with Interferon Beta or Glatiramer Acetate.
    Rojas-Morales E; Santos-López G; Hernández-Cabañas S; Arcega-Revilla R; Rosas-Murrieta N; Jasso-Miranda C; El-Kassis EG; Reyes-Leyva J; Sedeño-Monge V
    Int J Mol Sci; 2019 Dec; 21(1):. PubMed ID: 31905601
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Glatiramer acetate and IFN-beta act on dendritic cells in multiple sclerosis.
    Hussien Y; Sanna A; Söderström M; Link H; Huang YM
    J Neuroimmunol; 2001 Dec; 121(1-2):102-10. PubMed ID: 11730946
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interferon-beta1b for the treatment of multiple sclerosis.
    Lam S; Wang S; Gottesman M
    Expert Opin Drug Metab Toxicol; 2008 Aug; 4(8):1111-7. PubMed ID: 18680445
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of short-term interferon-β treatment on cytokines in multiple sclerosis: significant modulation of IL-17 and IL-23.
    Kürtüncü M; Tüzün E; Türkoğlu R; Petek-Balcı B; Içöz S; Pehlivan M; Birişik Ö; Ulusoy C; Shugaiv E; Akman-Demir G; Eraksoy M
    Cytokine; 2012 Aug; 59(2):400-2. PubMed ID: 22652415
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interferons-beta versus glatiramer acetate for relapsing-remitting multiple sclerosis.
    La Mantia L; Di Pietrantonj C; Rovaris M; Rigon G; Frau S; Berardo F; Gandini A; Longobardi A; Weinstock-Guttman B; Vaona A
    Cochrane Database Syst Rev; 2016 Nov; 11(11):CD009333. PubMed ID: 27880972
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Monocyte and Lymphocyte Activation and Regulation in Multiple Sclerosis Patients. Therapy Effects.
    González-Oria MC; Márquez-Coello M; Girón-Ortega JA; Argente J; Moya M; Girón-González JA
    J Neuroimmune Pharmacol; 2019 Sep; 14(3):413-422. PubMed ID: 30649665
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Alterations in serum levels of IL-17 in contrast to TNF-alpha correspond to disease-modifying treatment in relapsing-remitting multiple sclerosis.
    Trenova AG; Slavov GS; Manova MG; Draganaova-Filipova MN; Mateva NG; Miteva LD; Stanilova SA
    Scand J Clin Lab Invest; 2017 Jul; 77(4):283-288. PubMed ID: 28319417
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interferons-beta versus glatiramer acetate for relapsing-remitting multiple sclerosis.
    La Mantia L; Di Pietrantonj C; Rovaris M; Rigon G; Frau S; Berardo F; Gandini A; Longobardi A; Weinstock-Guttman B; Vaona A
    Cochrane Database Syst Rev; 2014 Jul; (7):CD009333. PubMed ID: 25062935
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The influence of glatiramer acetate on Th17-immune response in multiple sclerosis.
    Melnikov M; Sharanova S; Sviridova A; Rogovskii V; Murugina N; Nikolaeva A; Dagil Y; Murugin V; Ospelnikova T; Boyko A; Pashenkov M
    PLoS One; 2020; 15(10):e0240305. PubMed ID: 33126239
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [T-cell interferon-gamma, tumor necrosis factor-alpha and interleukin-6 receptor binding in patients with multiple sclerosis. Effects of interferon-beta-1b treatment].
    Bongioanni P; Romano MR; Boccardi B; Lombardo F; Moscato G; Mosti S; Baldini C; Nuti S; Meucci G; Rossi B
    Rev Neurol; 1999 Nov 16-30; 29(10):893-9. PubMed ID: 10637835
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Interferon gamma and interleukin 4 producing T cells in peripheral blood of multiple sclerosis patients undergoing immunomodulatory treatment.
    Franciotta D; Zardini E; Bergamaschi R; Andreoni L; Cosi V
    J Neurol Neurosurg Psychiatry; 2003 Jan; 74(1):123-6. PubMed ID: 12486283
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cytokines and disability in interferon-β-1b treated and untreated women with multiple sclerosis.
    Trenova AG; Slavov GS; Manova MG; Kostadinova II
    Arch Med Res; 2014 Aug; 45(6):495-500. PubMed ID: 25130430
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.